Epstein-Barr virus (EBV) infection in AIDS patients is associated with both B-cell lymphomas and oral hairy leukoplakia. The EBV immediate-early (IE) proteins, BZLF1 and BRLF1, mediate the switch between the latent and lytic forms of EBV infection. In addition, the IE proteins have a profound effect on the host cell environment. In this competitive grant renewal, we propose to continue our long-term studies on the role of the two EBV IE proteins in EBV-associated diseases. We hypothesize that the two EBV IE proteins are not only required to induce the lytic form of EBV infection, but may also help to support certain EBV-associated malignancies through a paracrine mechanism. We have recently discovered that BZLF1 preferentially binds to, and activates, the BRLF1 IE promoter only after it has been methylated over a CpG motif contained within a BZLF1 binding site. Thus, BZLF1 appears to be uniquely suited for activating the methylated form of the viral genome. We have also recently identified a new viral transactivator protein, BRRF1, and shown that BRRF1 collaborates with BRLF1 to induce lytic EBV infection. In addition, recent data from our laboratory suggest that paracrine factors released from lytically infected cells are required for the development of EBV-associated lymphomas in vivo.
Our specific aims are as follows.
In Specific Aim 1, we will compare and contrast how epigenetic modifications of the two IE viral promoters (including DNA methylation and histone acetylation) affect the ability of BZLF1 versus BRLF1 to disrupt viral latency, and determine whether the novel ability of BZLF1 to preferentially activate the methylated form of the BRLF1 IE promoter is important for BZLF1 function.
In Specific Aim 2, we will further investigate the mechanisms by which BRLF1 and BRRF1 both individually transactivate the BZLF1 IE promoter in EBV-negative cells, and collaborate to induce lytic infection in EBV-positive cells.
In Specific Aim 3, we will use wild-type, as well as BZLF1 - and BRLF1-knock-out viruses, to infect epithelial cells and determine if IE proteins are important for viral pathogenesis or transformation in these cells. The proposed studies should yield important insight into the multiple roles that lytic EBV proteins play in EBV-associated diseases.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR (04))
Program Officer
Daschner, Phillip J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Internal Medicine/Medicine
Schools of Medicine
Chapel Hill
United States
Zip Code
Hoebe, Eveline; Wille, Coral; Hagemeier, Stacy et al. (2018) Epstein-Barr Virus Gene BARF1 Expression is Regulated by the Epithelial Differentiation Factor ?Np63? in Undifferentiated Nasopharyngeal Carcinoma. Cancers (Basel) 10:
Kenney, Shannon C; Mertz, Janet E (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 26:60-8
Wille, Coral K; Nawandar, Dhananjay M; Panfil, Amanda R et al. (2013) Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol 87:935-50
Raver, Ryan M; Panfil, Amanda R; Hagemeier, Stacy R et al. (2013) The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. J Virol 87:8053-63
Hoebe, E K; Wille, C; Hopmans, E S et al. (2012) Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation. J Virol 86:11322-32
Robinson, Amanda R; Kwek, Swee Sen; Kenney, Shannon C (2012) The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog 8:e1002516
Hagemeier, Stacy R; Barlow, Elizabeth A; Meng, Qiao et al. (2012) The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol 86:13360-70
Ma, Shi-Dong; Yu, Xianming; Mertz, Janet E et al. (2012) An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 86:7976-87
Ryan, Julie L; Shen, You-Jun; Morgan, Douglas R et al. (2012) Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci 57:1887-98
Shaffer, Donald R; Savoldo, Barbara; Yi, Zhongzhen et al. (2011) T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117:4304-14

Showing the most recent 10 out of 53 publications